Clevexel Pharma SAS - Company Review
Clevexel Pharma SAS - Company ReviewSummary
Clevexel Pharma SAS (Clevexel) is a drug development company that develops drugs to treat diseases of the central nervous system. The company’s pipeline product portfolio includes CVXL-0107, a glutamate release inhibitor developed to improve the quality of life for Parkinson’s disease patients; CVXL-0069, a dual A2A/A1 antagonist that concentrates on the treatment of motor and non-motor symptoms of Parkinson’s disease. It operates drug development site covering all phases from preclinical to early clinical developments. Clevexel offers drug development tools to its partners and clients. The company works in partnership with Institut du Cerveau et de la Moelle Epiniere for development of new treatments in the field of neurodegenerative diseases. Clevexel is headquartered in Paris, France.
This comprehensive company report of Clevexel Pharma SAS provides you with company's businesses and operations information.
The profile contains critical company information including,
- Company Overview - A detailed description of the company's operations and business divisions.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
GlobalData is a one-stop solution for actionable insight into the pharmaceutical and medical device sectors. Together with the best team of researchers, analysts, epidemiologists and consultants, and an unmatched suite of proprietary databases, we provide high-quality, accurate and transparent insight that can help you achieve growth and increase business value.
Our valuable research and consulting solutions ensure you stay at the forefront of the industry by integrating accurate market forecasts and healthcare analytics on the latest trends and developments. Among other benefits, our informed healthcare industry perspectives have assisted businesses based across the pharmaceuticals, biotechnology and medical equipment markets in making strategic decisions that have increased the value of their products and services.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.